A case of ventricular asystole without escape rhythm 4days after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy with drug-resistant paroxysmal atrial fibrillation  by Ohtsubo, Mitsunori et al.
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Summary  A  42-year-old  man  with  a  more  than  10-year  history  of  hypertrophic  obstructive
cardiomyopathy,  but  no  history  of  heart  failure  or  syncope,  had  left  ventricular  outﬂow  tract
pressure gradient  (LVOT-PG)  of  50—80  mmHg  on  Doppler  echocardiography.  In  June  2010,  he
experienced  general  malaise  on  effort,  and  LVOT-PG  increased  to  124  mmHg.  Two  months  later,
he suffered  a  transient  ischemic  attack,  complicated  with  atrial  ﬁbrillation  (AF).  He  under-
went cardiac  deﬁbrillation  and  was  prescribed  amiodarone,  but  the  arrhythmia  recurred  easily.
Therefore,  percutaneous  transluminal  septal  myocardial  ablation  (PTSMA)  was  performed  to
prevent AF.  The  procedure  entailed  transient  complete  atrioventricular  block  (CAVB),  which
was resolved  after  a  few  hours.  Four  days  later,  CAVB  recurred  and  advanced  to  fatal  ventricu-
lar asystole  without  escape  rhythm.  The  patient  was  resuscitated  instantaneously  and  recovered
without brain  damage.  Finally,  a  DDD  permanent  pacemaker  was  implanted  10  days  after  theVentricular  asystole
procedure.  Except  for  conduction  problems,  his  cardiac  condition  was  good  after  PTSMA,  as
paroxysmal  AF  disappeared  and  LVOT-PG  was  markedly  decreased.
CAVB is  a  well-known  complication  of  PTSMA,  but  fatal  ventricular  asystole  several  days  after
the procedure  is  rare.  Intensive  care  is  required  after  PTSMA  implementation.
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ntroductionercutaneous  transluminal  septal  myocardial  ablation
PTSMA)  is  a  promising  procedure  to  improve  clinical
ymptoms  and  decrease  left  ventricular  outﬂow  tract  pres-
ure  gradient  (LVOT-PG)  in  patients  with  hypertrophic
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bVentricular  asystole  several  days  after  percutaneous  translu
obstructive  cardiomyopathy  (HOCM)  [1].  Complete  atri-
oventricular  block  (CAVB)  is  a  known  complication  of  this
procedure  [2—8]. However,  to  our  knowledge,  there  have
been  no  reports  regarding  cases  of  ventricular  asystole  sev-
eral  days  after  PTSMA.  Here,  we  present  a  case  of  ventricular
asystole,  which  advanced  from  CAVB,  4  days  after  PTSMA.
Case report
A  42-year-old  man  with  HOCM  had  been  treated  for  more
than  10  years.  Echocardiography  was  performed  on  a  reg-
ular  basis,  and  revealed  systolic  anterior  movement  (SAM)
of  the  mitral  valve  (Fig.  1A)  and  mild  to  moderate  mitral
regurgitation  ﬂow.  Doppler  echocardiography  showed  LVOT-
PG  of  50—80  mmHg.  The  patient  had  been  well  and  had  no
signs  of  heart  failure,  syncope,  or  arrhythmia.  However,  he
experienced  general  malaise  on  physical  exercise  in  June
2010.  Doppler  echocardiography  showed  that  LVOT-PG  had
increased  to  124  mmHg  (Fig.  1B)  and  mitral  regurgitation
showed  deterioration.
In August  2010,  he  felt  loss  of  muscle  strength  in  the
right  upper  and  lower  extremities  and  visited  a  neuro-
surgeon.  Brain  magnetic  resonance  imaging  (MRI)  revealed
no  signiﬁcant  abnormalities,  and  his  symptoms  recovered
rapidly.  Therefore,  a  diagnosis  of  transient  ischemic  attack
was  made.  Meanwhile,  electrocardiography  revealed  atrial
ﬁbrillation  (AF),  which  was  the  ﬁrst  arrhythmia  event  in
this  patient.  He  was  then  transferred  to  our  institute,
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Figure  1  Pre-percutaneous  transluminal  septal  myocardial  ablatio
M-mode echocardiography  (A),  and  left  ventricular  outﬂow  tract  pr
diography (B).  Thirty-three  days  after  PTSMA,  LVOT-PG  decreased  tol  septal  myocardial  ablation  e111
nd  anticoagulant  agents  and  amiodarone  were  prescribed.
ransesophageal  echocardiography  revealed  severe  smoke-
ike  echo  in  the  left  atrium,  but  no  obvious  thrombi  were
ecognized.  Thereafter,  he  underwent  cardiac  deﬁbrillation
nd  his  cardiac  rhythm  returned  to  sinus  rhythm.  However,
F  recurred  5  days  and  12  days  later,  and  he  underwent
ardiac  deﬁbrillation  on  both  occasions.  Despite  medi-
al  therapy,  including  amiodarone,  AF  recurred  frequently
ithin  a  short  period.  Therefore,  we  decided  to  perform
TSMA  to  prevent  the  arrhythmia.
Baseline  cardiac  catheterization  revealed  normal  coro-
ary  arteries.  The  left  anterior  descending  artery  had  a
arge  ﬁrst  septal  branch  (Fig.  2A),  which  was  thought  to  be
uitable  for  ablation.  Left  ventriculography  demonstrated
ypercontraction  and  moderate  mitral  regurgitation  ﬂow.
n  the  day  of  PTSMA,  a  temporary  pacing  catheter  was
laced  in  the  apex  of  the  right  ventricle  to  prevent  CAVB.
 4  Fr  pigtail  catheter  was  inserted  into  the  left  ventri-
le  and  a  7  Fr  guiding  catheter  was  engaged  in  the  left
oronary  artery  ostium,  so  simultaneous  LVOT-PG  could  be
valuated.  An  over-the-wire  balloon  2.5  mm  in  diameter  and
 mm  in  length  was  located  to  the  proximal  portion  of  the
arge  ﬁrst  septal  branch.  We  attempted  contrast  myocar-
ial  echocardiography  (CME)  to  delineate  the  area  supplied
y  the  index  septal  branch.  Echo  contrast  (Levovist;  Bayer
chering  Pharma,  Berlin,  Germany)  was  injected  through  the
atheter  shaft,  but  the  circulation  area  could  not  be  con-
rmed  because  of  technical  failure.  Pre-procedural  LVOT-PG
as  83  mmHg,  but  it  decreased  to  61  mmHg  after  15  min  of
n  (PTSMA),  systolic  anterior  movement  (SAM)  was  indicated  by
essure  gradient  (LVOT-PG)  was  124  mmHg  on  Doppler  echocar-
 11  mmHg  (C)  and  SAM  disappeared  (D).
e112  M.  Ohtsubo  et  al.
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iigure  2  (A)  Before  percutaneous  transluminal  septal  myoc
ranch (arrowhead).  (B)  After  ethanol  injection,  a  large  septal  
robationary  balloon  inﬂation.  Thereafter,  bolus  injection
f  2  mL  of  pure  ethanol  was  conducted  through  the  catheter
haft  (Fig.  2B).  Pre-procedural  electrocardiography  revealed
omplete  right  bundle  branch  block  (CRBBB)  without  atri-
ventricular  block  (Fig.  3A),  but  CAVB  was  conﬁrmed  after
olus  ethanol  injection.  LVOT-PG  dropped  to  28  mmHg  after
he  procedure.  CAVB  was  resolved  a  few  hours  later,  and  Q
ave  appeared  in  V1-2  the  following  day  (Fig.  3B).  Creatine
inase  level  increased  to  1411  IU/L  and  dropped  thereafter.
The  patient  was  well,  and  the  temporary  pacing  catheter
as  removed  2  days  after  PTSMA.  However,  4  days  after
he  procedure,  the  patient  lost  consciousness  and  exhibited
onvulsions.  The  nursing  staff  noticed  his  change  immedi-
tely  and  began  cardiac  resuscitation,  and  his  heartbeat
as  restarted  after  injection  of  epinephrine.  Fortunately,
e  recovered  without  any  brain  damage.  A  review  of  ambu-
atory  electrocardiograms  indicated  CAVB,  which  advanced
o  ventricular  asystole.  Only  P  waves  were  shown,  but
RS  complexes  disappeared  suddenly  (Fig.  3C  and  D).  The
emporary  pacing  catheter  was  reintroduced,  and  a  DDD
ermanent  pacemaker  was  implanted  10  days  after  the  pro-
edure.
With  the  exception  of  the  above  conduction  problem,
linical  symptoms  and  cardiohemodynamics  were  amelio-
ated  after  PTSMA.  Paroxysmal  AF  and  general  malaise
n  effort  disappeared  completely.  On  Doppler  echocardio-
raphy,  LVOT-PG  was  66  mmHg,  25  mmHg,  11  mmHg,  and
1  mmHg  4,  9,  19,  and  33  days  after  PTSMA,  respectively
Fig.  1C).  Furthermore,  SAM  disappeared  (Fig.  1D),  and
itral  regurgitation  was  also  ameliorated.  Left  atrium
hamber  size  decreased  from  50  mm  to  42  mm.
iscussion
ur  patient  demonstrated  CAVB  not  only  immediately  after
thanol  injection,  but  also  4  days  after  PTSMA.  The  ﬁrst  CAVB
as  transient,  whereas  the  second  advanced  to  ventricular
systole  without  escape  rhythm.  Fortunately,  the  patient
as  resuscitated  successfully,  and  recovered  without  any
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rl  ablation,  left  coronary  angiography  revealed  a  large  septal
ch  was  ablated  (white  arrow).
rain  damage.  The  reason  why  escape  ventricular  beats  did
ot  appear  remains  unknown.  To  our  knowledge,  there  have
een  no  previous  reports  of  CAVB  advancing  to  ventricular
systole  several  days  after  PTSMA.
PTSMA  has  some  complications,  the  most  common  of
hich  is  CAVB  [2—8]. Accordingly,  intensive  care  is  essen-
ial  during  and  after  this  procedure.  CAVB  usually  emerges
mmediately  after  ethanol  injection,  and  some  patients
equire  a  DDD  permanent  pacemaker.  On  the  other  hand,
here  have  been  reports  of  cases  showing  intermittent  or
ate  conduction  disturbance.  ten  Berg  et  al.  [2]  reported
 case  of  recurrent  CAVB  after  PTSMA,  and  Faber  et  al.  [3]
escribed  late  conduction  disturbance  that  occurred  11  days
fter  PTSMA.  These  reports  emphasized  the  need  for  close
hythmological  monitoring  for  several  days  following  the
ntervention  [4].
In  our  patient,  we  placed  a  temporary  pacemaker  before
TSMA  to  prevent  bradycardia  events.  Transient  CAVB  pre-
ented  for  only  a  few  hours  and  was  resolved  thereafter,
o  the  temporary  pacemaker  was  removed  2  days  after  the
rocedure.  However,  recurrence  of  CAVB  and  subsequent
atal  ventricular  asystole  occurred  a  further  2  days  later.
herefore,  2-day  placement  of  a  temporary  pacemaker  was
nsufﬁcient  in  this  case.  It  is  not  clear  how  long  the  tempo-
ary  pacemaker  should  be  used,  and  a  standard  management
rotocol  for  PTSMA  will  be  required  in  the  future.
Chang  et  al.  [5]  examined  the  incidence  and  determi-
ants  of  CAVB  after  PTSMA.  They  reported  that  high  age,
emale  gender,  left  bundle  branch  block  (LBBB),  and  ﬁrst-
egree  atrioventricular  block  were  predictors  of  permanent
acemaker  requirement  as  baseline  characteristics.  Our
atient  was  middle-aged,  male,  and  preprocedural  electro-
ardiography  did  not  demonstrate  LBBB  or  atrioventricular
lock.  Thus,  these  background  factors  were  not  compat-
ble  with  this  case.  Chang  et  al.  [5]  also  reported  the
ncidence  of  atrioventricular  complications  related  to  tech-
ical  aspects,  such  as  bolus  ethanol  injection,  >2  ethanol
njected  septal  branches,  and  absence  of  CME.  Previous
tudies  indicated  that  slow  ethanol  injection  contributed  to
eduction  of  atrioventricular  block  [6],  but  we  conducted
Ventricular  asystole  several  days  after  percutaneous  transluminal  septal  myocardial  ablation  e113
Figure  3  (A)  Preprocedural  electrocardiography  revealed  complete  right  bundle  branch  block.  (B)  Abnormal  Q  waves  were  seen
in V1-2  on  the  day  after  percutaneous  transluminal  septal  myocardial  ablation  (PTSMA).  (C)  Four  days  after  PTSMA,  the  patient  lost
consciousness.  Review  of  ambulatory  electrocardiograms  revealed  sudden  ventricular  asystole,  as  only  P  waves  were  observed  but
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sQRS disappeared  suddenly.  (D)  Higher  magniﬁcation  of  the  boxe
bolus  ethanol  injection.  If  we  had  performed  ethanol  injec-
tion  slowly,  the  transient  CAVB  that  occurred  immediately
after  the  procedure  may  have  been  avoided.  However,  it
was  unclear  whether  slow  ethanol  injection  could  prevent
recurrence  of  CAVB  and  ventricular  asystole.  By  employing
CME,  Faber  et  al.  [3]  reported  that  the  frequency  of  CAVB
could  be  reduced.  When  patients  have  several  coronary  sep-
tal  branches,  selective  echo  contrast  agent  injection  into
each  branch  can  identify  its  circulation  area  and  can  con-
ﬁrm  the  appropriate  branch  for  ethanol  injection.  Using  this
technique,  useless  ethanol  injection  can  be  avoided  and
total  ethanol  volume  will  be  limited.  Hence,  the  volume  of
b
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aa  in  (C).
ecrotized  myocardium  will  also  be  limited,  and  therefore
TSMA  with  CME  will  cause  less  conduction  disturbance.  We
lso  performed  CME,  but  unfortunately  could  not  identify
he  circulation  area  of  the  septal  branch  due  to  technical
ailure.  However,  our  patient  had  only  one  large  ﬁrst  septal
ranch,  and  it  was  therefore  the  sole  target  vessel.  Accord-
ngly,  we  would  have  injected  ethanol  into  the  ‘‘target’’
eptal  branch  irrespective  of  CME,  even  if  it  had  been  possi-
le  to  identify  the  circulation  area.  It  is  possible  that  large
eptal  branch  ablation  could  be  related  to  CAVB.
HOCM  with  high  LVOT-PG  and  heart  failure  on  drug  ther-
py  are  considered  indications  for  PTSMA.  Drug-resistant
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aroxysmal  AF  is  also  regarded  as  an  indication  for
TSMA.  Our  patient  showed  frequent  AF  despite  amiodarone
herapy,  but  it  disappeared  after  PTSMA.  Comparison  of
chocardiography  ﬁndings  before  and  after  the  procedure
ndicated  that  not  only  LVOT-PG  decreased,  but  mitral  regur-
itation  ﬂow  was  also  ameliorated,  SAM  was  resolved,  and
he  left  atrium  showed  a  reduction  in  size.  We  speculated
hat  contraction  disturbance  of  basal  hypertrophied  septal
yocardium  led  to  the  resolution  of  SAM,  which  caused  a
ecrease  in  systolic  mitral  regurgitation  ﬂow  and  a  reduction
f  the  left  atrium  chamber  size.  Hosokawa  et  al.  [9]  reported
imilar  speculations  about  the  effectiveness  of  PTSMA  in  pre-
enting  supraventricular  arrhythmia.  They  concluded  that
mooth  blood  inﬂow  into  the  left  ventricle  and  decreased
trial  wall  pressure  stress  were  the  key  factors  in  its  useful-
ess.
In  conclusion,  CAVB  recurred  and  advanced  to  ventricular
systole  without  escape  rhythm  several  days  after  PTSMA.
onger  intensive  care  is  necessary  after  the  procedure.
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